Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hallberg

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Cancer|March 12, 2026
A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancerGayle S Jameson, Denise J Roe, Erkut Borazanci, et al.
Allergy|May 2, 2015
Phenotyping asthma, rhinitis and eczema in MeDALL population-based birth cohorts: an allergic comorbidity clusterJ Garcia-Aymerich, M Benet, Y Saeys, et al.
Journal of Medical Genetics|May 12, 2017
The <i>BRCA1</i> c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortiumSetareh Moghadasi, Huong D Meeks, Maaike Pg Vreeswijk, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Cancer|March 12, 2026
A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancerGayle S Jameson, Denise J Roe, Erkut Borazanci, et al.
Allergy|May 2, 2015
Phenotyping asthma, rhinitis and eczema in MeDALL population-based birth cohorts: an allergic comorbidity clusterJ Garcia-Aymerich, M Benet, Y Saeys, et al.
Journal of Medical Genetics|May 12, 2017
The <i>BRCA1</i> c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortiumSetareh Moghadasi, Huong D Meeks, Maaike Pg Vreeswijk, et al.
Pageof 5